Search

Your search keyword '"Boakye, D. A."' showing total 147 results
Start Over Author "Boakye, D. A."
147 results on '"Boakye, D. A."'

2. Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses

Author

Boakye D, Walter V, Martens UM, Chang-Claude J, Hoffmeister M, Jansen L, and Brenner H

Subjects
Comorbidity, Functional status, Treatment selection bias, Chemotherapy, Survival, Colorectal neoplasm, Infectious and parasitic diseases, RC109-216
Abstract

Daniel Boakye1,2, Viola Walter1, Uwe M Martens3, Jenny Chang-Claude4, Michael Hoffmeister1, Lina Jansen1,*, Hermann Brenner1,5,6,* 1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany; 3SLK-Clinics, Cancer Center Heilbronn-Franken, Heilbronn, Germany; 4Unit of Genetic Epidemiology, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 5Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany; 6German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany*These authors contributed equally to this workCorrespondence: Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg 69120, GermanyTel +49 622 142 1300Fax +49 622 142 1302Email h.brenner@dkfz.deIntroduction: Propensity score methods are increasingly used to address confounding related to treatment selection in observational studies. Studies estimating the effect of chemotherapy in colon cancer (CC) patients, however, often lacked information on pertinent comorbidities and functional status (FS). We assessed to what extent comorbidities and FS impact treatment decisions in colorectal cancer patients and explain the benefit of chemotherapy in stage III CC patients.Methods: Stage II-III colorectal cancer patients diagnosed in 2003–2014 and recruited into a population-based study were included (N=1102). Associations of comorbidity and FS with treatment patterns were examined with multivariable logistic regression. The contribution of lower comorbidity and higher FS to the benefit of chemotherapy was estimated with propensity score weighted Cox models in 430 stage III CC patients who were followed over a median time of 4.7 years.Results: In stage II (high-risk) and III CC patients, Charlson comorbidity scores 1, 2 and 3+ were associated with 57%, 66% and 70% lower odds of chemotherapy use, respectively. In combination with older age and poor FS, comorbidity was associated with 97% and 83% decreased odds of adjuvant chemotherapy use in CC and rectal cancer patients, respectively. In stage III CC patients, lower comorbidity and higher FS explained 38% and 24% of the overall and disease-specific survival benefits of chemotherapy, respectively. Selection bias was observed even in the comprehensive models, as chemotherapy was still associated with substantially higher non-disease-specific survival (hazard ratio (HR): 0.66; 95% confidence interval (CI): 0.46–0.92), especially in patients

Published
2019

4. Self-reported beta-lactam allergy in government and private hospitals in Cape Town, South Africa

Author

Day, C, primary, Deetlefs, M, additional, O’Brien, A, additional, Smith, J, additional, Boyd, M, additional, Embling, N, additional, Patel, S, additional, Moody, K, additional, Ramabele, T, additional, Budge, A, additional, Tarwa, T, additional, Jim, O, additional, Maharaj, T, additional, Pandy, S, additional, Abrahams, J-M, additional, Panieri, A, additional, Verhage, S, additional, Van der Merwe, M, additional, Geragotellis, A, additional, Amanjee, W, additional, Joseph, C, additional, Zhao, Z, additional, Moosa, S, additional, Bunting, M, additional, Pulani, Y, additional, Mukhari, P, additional, De Paiva, M, additional, Deyi, G, additional, Wonkam, R P, additional, Mancotywa, N, additional, Dunge, A, additional, Msimanga, T, additional, Singh, A, additional, Monnaruri, O, additional, Molale, B, additional, Butler, T A G, additional, Browde, K, additional, Muller, C, additional, Van der Walt, J, additional, Whitelaw, R, additional, Cronwright, D, additional, Sinha, S, additional, Binase, U, additional, Francis, I, additional, Boakye, D, additional, Dlamini, S, additional, Mendelson, M, additional, and Peter, J, additional

Published
2023
Full Text
View/download PDF

5. Description, Biology, and Medical Significance of Leishmania (Mundinia) Chancei n. sp. (Kinetoplastea: Trypanosomatidae) from Ghana and Leishmania (Mundinia) Procaviensis n. sp. (Kinetoplastea: Trypanosomatidae) from Namibia

Author

Kwakye-Nuako, G., Mosore, M.-T., Boakye, D., and Bates, P.A.

Subjects
Parasitology, Ecology, Evolution, Behavior and Systematics
Abstract

Genetic and phylogenetic analysis was performed on 2 isolates of Leishmania using DNA sequence data from the RNA polymerase II large subunit gene and the ribosomal protein L23a intergenic sequence. This showed the isolates to represent 2 new species within the subgenus Leishmania (Mundinia). The addition of Leishmania (Mundinia) chancei and Leishmania (Mundinia) procaviensis creates a total of 6 named species to date within this recently described subgenus of parasitic protozoa, containing both human pathogens and nonpathogens. Their widespread geographical distribution, basal phylogenetic position within the genus Leishmania, and probable non-sand fly vectors make these L. (Mundinia) species of significant medical and biological interest.

Published
2023

6. Relationship between eosinophil cationic protein and infection intensity in a schistosomiasis endemic community in Ghana

Author

Asuming-Brempong E, Gyan B, Amoah AS, van der Puije W, Bimi L, Boakye D, and Ayi I

Subjects
Arctic medicine. Tropical medicine, RC955-962
Abstract

Elias Asuming-Brempong,1–3 Ben Gyan,2 Abena Serwaa Amoah,3,4 William van der Puije,3,4 Langbong Bimi,1 Daniel Boakye,3 Irene Ayi3 1Department of Animal Biology and Conservation Science, University of Ghana, Legon, Ghana; 2Immunology Department, 3Parasitology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana; 4Parasitology Department, Leiden University Medical Centre, Leiden, The NetherlandsBackground: Recent studies have shown the urine filtration and Kato-Katz techniques to significantly underestimate infection intensity in Schistosoma haematobium and Schistosoma mansoni infections, respectively. Infection intensity determination by these methods improves only with increasing number of samples collected per participant. This implies tedious and lengthy periods of sample processing and analysis by microscopy examination, hence the increased chances of experimental errors. This study sought to determine the relationship between levels of eosinophil cationic protein (ECP) and infection intensity by egg count both in S. haematobium and S. mansoni single and coinfections.Methods: This was a cross-sectional study carried out in Pakro, a periurban community in Ghana, involving a total of 308 participants. Each provided urine and stool samples, which were processed using the filtration and Kato-Katz techniques, respectively. Processed samples were examined by microscopy. Aliquots of urine from 73 participants were analyzed for levels of ECP using an ECP enzyme-linked immunosorbent assay kit.Results: Of the 308 urine samples examined, 59 (19.15%) were positive for S. haematobium. Significant association was observed between sex and S. haematobium infection intensity by egg count (P

Published
2015

7. Self-reported beta-lactam allergy: inpatients in government funded and privately funded hospitals Cape Town, South Africa

Author

Day, Cascia, primary, Deetlefs, M., additional, O’Brien, A., additional, Smith, J., additional, Boyd, M., additional, Embling, N., additional, Patel, S., additional, Moody, K., additional, Ramabele, T., additional, Budge, A., additional, Tarwa, Tapiwa Tavarwisa, additional, Jim, O., additional, Maharaj, T., additional, Pandy, S., additional, Abrahams, JM., additional, Panieri, A., additional, Verhage, S., additional, Merwe, M. van der, additional, Geragotellis, A., additional, Amanjee, W., additional, Joseph, C., additional, Zhao, Z., additional, Moosa, S., additional, Bunting, M., additional, Pulani, Yanelisa, additional, Mukhari, P., additional, Paiva, M. de, additional, Deyi, G., additional, Wonkam, R. Peigou, additional, Mancotywa, N., additional, Dunge, A., additional, Msimanga, T., additional, Singh, A., additional, Monnaruri, O., additional, Molale, B., additional, Butler, T., additional, Browde, K., additional, Muller, C., additional, Walt, J. Van Der, additional, Whitelaw, R., additional, Cronwright, D., additional, Parker, N., additional, Sinha, S., additional, Binase, U., additional, Francis, I., additional, Boakye, D., additional, Dlamini, S., additional, Mendelson, M., additional, and PETER, Jonny, additional

Published
2022
Full Text
View/download PDF

13. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease

Author

Benbow, M. Eric, Williamson, Heather, Kimbirauskas, Ryan, McIntosh, Mollie D., Kolar, Rebecca, Quaye, Charles, Akpabey, Felix, Boakye, D., Small, Pam, and Merritt, Richard W.

Subjects
Company distribution practices, Buruli ulcer -- Risk factors, Buruli ulcer -- Genetic aspects, Buruli ulcer -- Control, Buruli ulcer -- Research, Mycobacteria -- Health aspects, Mycobacteria -- Genetic aspects, Mycobacteria -- Distribution, Mycobacteria -- Control, Mycobacteria -- Research, Mycobacterium -- Health aspects, Mycobacterium -- Genetic aspects, Mycobacterium -- Distribution, Mycobacterium -- Control, Mycobacterium -- Research
Abstract

Buruli ulcer is a necrotizing skin disease caused by Mycobacterium ulcerans and associated with exposure to aquatic habitats. To assess possible transmission of M. ulcerans by aquatic biting insects, we [...]

Published
2008

17. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper

Author

Bousquet, J., Schünemann, H. J., Zuberbier, T., Bachert, C., Baena-Cagnani, C. E., Bousquet, P. J., Brozek, J., Canonica, G. W., Casale, T. B., Demoly, P., Gerth van Wijk, R., Ohta, K., Bateman, E. D., Calderon, M., Cruz, A. A., Dolen, W. K., Haughney, J., Lockey, R. F., Lötvall, J., OʼByrne, P., Spranger, O., Togias, A., Bonini, S., Boulet, L. P., Camargos, P., Carlsen, K. H., Chavannes, N. H., Delgado, L., Durham, S. R., Fokkens, W. J., Fonseca, J., Haahtela, T., Kalayci, O., Kowalski, M. L., Larenas-Linnemann, D., Li, J., Mohammad, Y., Mullol, J., Naclerio, R., OʼHehir, R. E., Papadopoulos, N., Passalacqua, G., Rabe, K. F., Pawankar, R., Ryan, D., Samolinski, B., Simons, F. E. R., Valovirta, E., Yorgancioglu, A., Yusuf, O. M., Agache, I., Aït-Khaled, N., Annesi-Maesano, I., Beghe, B., Ben Kheder, A., Blaiss, M. S., Boakye, D. A., Bouchard, J., Burney, P. G., Busse, W. W., Chan-Yeung, M., Chen, Y., Chuchalin, A. G., Costa, D. J., Custovic, A., Dahl, R., Denburg, J., Douagui, H., Emuzyte, R., Grouse, L., Humbert, M., Jackson, C., Johnston, S. L., Kaliner, M. A., Keith, P. K., Kim, Y. Y., Klossek, J. M., Kuna, P., Le, L. T., Lemiere, C., Lipworth, B., Mahboub, B., Malo, J. L., Marshall, G. D., Mavale-Manuel, S., Meltzer, E. O., Morais-Almeida, M., Motala, C., Naspitz, C., Nekam, K., Niggemann, B., Nizankowska-Mogilnicka, E., Okamoto, Y., Orru, M. P., Ouedraogo, S., Palkonen, S., Popov, T. A., Price, D., Rosado-Pinto, J., Scadding, G. K., Sooronbaev, T. M., Stoloff, S. W., Toskala, E., van Cauwenberge, P., Vandenplas, O., van Weel, C., Viegi, G., Virchow, J. C., Wang, D. Y., Wickman, M., Williams, D., Yawn, B. P., Zar, H. J., Zernotti, M., and Zhong, N.

Published
2010
Full Text
View/download PDF

19. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen)

Author

Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena-Cagnani, C. E., Canonica, G. W., van Weel, C., Agache, I., Aït-Khaled, N., Bachert, C., Blaiss, M. S., Bonini, S., Boulet, L.-P., Bousquet, P.-J., Camargos, P., Carlsen, K.-H., Chen, Y., Custovic, A., Dahl, R., Demoly, P., Douagui, H., Durham, S. R., van Wijk, R. Gerth, Kalayci, O., Kaliner, M. A., Kim, Y.-Y., Kowalski, M. L., Kuna, P., Le, L. T. T., Lemiere, C., Li, J., Lockey, R. F., Mavale-Manuel, S., Meltzer, E. O., Mohammad, Y., Mullol, J., Naclerio, R., OʼHehir, R. E., Ohta, K., Ouedraogo, S., Palkonen, S., Papadopoulos, N., Passalacqua, G., Pawankar, R., Popov, T. A., Rabe, K. F., Rosado-Pinto, J., Scadding, G. K., Simons, F. E. R., Toskala, E., Valovirta, E., van Cauwenberge, P., Wang, D.-Y., Wickman, M., Yawn, B. P., Yorgancioglu, A., Yusuf, O. M., Zar, H., Annesi-Maesano, I., Bateman, E. D., Kheder, A. Ben, Boakye, D. A., Bouchard, J., Burney, P., Busse, W. W., Chan-Yeung, M., Chavannes, N. H., Chuchalin, A., Dolen, W. K., Emuzyte, R., Grouse, L., Humbert, M., Jackson, C., Johnston, S. L., Keith, P. K., Kemp, J. P., Klossek, J.-M., Larenas-Linnemann, D., Lipworth, B., Malo, J.-L., Marshall, G. D., Naspitz, C., Nekam, K., Niggemann, B., Nizankowska-Mogilnicka, E., Okamoto, Y., Orru, M. P., Potter, P., Price, D., Stoloff, S. W., Vandenplas, O., Viegi, G., and Williams, D.

Published
2008

20. Trente ans de lutte contre l’onchocercose en Afrique de l’Ouest. Traitements larvicides et protection de l’environnement

Author

A. Boatin, Boakye, Abban, E.K., Abban, K., Abban, K. E., Abban, Kofi Eddie, Agoua, H., Akpoboua, K.L.B., Akpoboua, L. K. B., Akpoboua, L.K.B., Alley, E. S., Alley, E.S., Alley, Edoh S., Antwi, L. A. K., Ba, O., Back, C., Baker, R. H. A., Baker, R.H.A., Baldry, David, Bihoum, M., Bissan, Y., Boakye, D., Boakye, D.A., Boakye, Daniel Adjei, Boatin, B., Boatin, B.A., Boatin, Boakye A, Boussinesq, M., Calamari, D., Calamari, Davide, Crosa, G., Crosa, Giuseppe, Curtis, M.S., Dadzie, K. Y., Dadzie, K.Y, Dadzie, K.Y., Dadzie, Kofi Yankum, Davies, J.B., Dejoux, C., Dejoux, Claude, Diop, M.E., Diop, Moussa Elimane, Elouard, J.-M., Elouard, Jean Marc, Elouard, Jean-Marc, Escaffre, Henri, Fairhurst, C., Fairhurst, C.P., Fermon, Y., Fermon, Yves, Gibon, F. M., Gibon, François Marie, Guillet, P., Guillet, Pierre, Hougard, J-M., Hougard, J.-M., Hougard, J.M., Hougard, Jean-Marc, Jamnback, Hugo, Jestin, Jean Marie, Jestin, Jean-Marie, Karam, Marc, Kondé, F., Kondé, Fafondé, Kurtak, D.C., Kurtak, Dan, Lapetite, Jean-Marc, Lévêque, C., Meredith, Stefanie E.O., Merona, Bernard de, Meyer, Rolf, Molyneux, D.H., Mosha, F.W., Nabé, K., Nabé, Kélétigui, Ocran, Michael, Odei, M., Ouedraogo, Moussa, Paugy, D., Paugy, Didier, Philippon, Bernard, Piessens, Willy F., Post, R.J., Poudiougo, P., Quillévéré, D., Quillévéré, Daniel, Remme, J., Renaud, Pierre, Samba, E. M., Samba, E.M., Samman, J., Sarbib, Jean-Louis, Sékétéli, A., Servat, Eric, Simier, M., sole, G. De, Statzner, Bernhard, Surtees, D.P., Tapsoba, J.-M., Tapsoba, Joseph-Marie, Tholley, D., Thomas, M. Pugh, Toe, Laurent, Traoré, K., Traoré, Kassoum, Troubat, Jean-Jacques, Unnasch, Thomas R., Wilson, M. D., Wirth, Dyann F., Yamaego, L., Yaméogo, L, Yaméogo, L., Yaméogo, Laurent, Zimmerman, Peter A., Yaméogo, Laurent, Levêque, Christian, and Hougard, Jean-Marc

Subjects
Surveillance, RNK, protection de l’écosystème, insecticide biologique, Côte d’Ivoire, Environmental Studies, onchocercose, vecteur, milieu aquatique, larve, insecticide chimique, NAT011000, méthode de lutte, parasite
Abstract

La lutte contre l'onchocercose, ou cécité des rivières, une maladie parasitaire endémique, fut entreprise en Afrique de l'Ouest dans une perspective do développement durable. Tous les moyens technologiques disponibles ont de ce fait été mobilisés pour le contrôle du vecteur, une simulie, puis du parasite responsables de cette maladie, par le Programme de Lutte contre l’Onchocercose en Afrique de l'Ouest (OCP). La lutte antivectorielle consistant en épandages d’insecticides chimiques sur les sites de développement de la simulie dans les rivières, il est apparu indispensable d’assurer la sauvegarde de l’environnement aquatique qui fournit aux communautés riveraines eau et ressources biologiques. Les technologies les plus modernes ont été mises en œuvre dès leur mise au point, pour combattre la maladie, contribuant ainsi à la protection de ce milieu. Le programme de surveillance écologique des rivières traitées par des larvicides anti-simulies a été mis en place dès le lancement d’OCP. et assuré par des spécialistes de I' hydrobiologie des pays africains participants du Programme, sous la supervision d’un groupe international d’experts indépendants, le Groupe Écologique. OCP est incontestablement un succès aussi bien pour ce qui est du contrôle de la maladie que de la protection de l'environnement. Il est l'exemple unique au monde d’un programme de santé publique de longue durée qui depuis son origine a mis en œuvre tout ce qui était possible pour harmoniser les enjeux de l’amélioration de la santé et ceux de la protection de l’environnement. Il s'est achevé avec la satisfaction de laisser aux générations montantes un environnement non dégradé et des vallées libérées de l’onchocercose, qui permettront d’accroître la productivité agricole des pays africains. The control of onchocerciasis, or river blindness, an endemic parasitic disease, was implemented in West Africa in the perspective of sustainable development AH the available technological means to fight this disease, by way of the control of its blackfly vector, then its parasite, were therefore implemented by the Onchocerciasis Control Programme in West Africa (OCP). Vector control being achieved through applications of chemicals on its river breeding sites, it was necessary, at the same time, to fight for the preservation of the aquatic environment, which supplies the communities that live along the rivers with water and biological resources. This was the spirit in which the OCP was set up and implemented, and the most modem technologies were used as they become available to fight the disease, thus facilitating the preservation of the aquatic environment. This Programme has indisputably been a success as regards the control of the disease as also from the point of view of the preservation of the environment The aquatic monitoring programme of the rivers under treatment with anti-simulid larvicides was set up right from the very beginning, and performed by national experts of the Participating Countries of the Programme, under the aegis of a group of international independent experts, the Ecological Croup The Onchocerciasis Control Programme in West Africa is an unique example in the world of a long-term public health programme which has made every effort possible from its inception to adequately combine health and environment issues. It ended with the satisfaction of bequeathing to the coming generations a non degraded environment and valleys freed from onchocerciasis which would increase the agricultural productivity of the countries.

Published
2019

21. Progress in controlling the reinvasion of wind borne vectors into the western area of the Onchocerciasis Control Programme in West Africa

Author

Baker, R. H. A., Guillet, P., Sékétéli, A., Poudiougo, P., Boakye, D., Wilson, M. D., and Bissan, Y.

Subjects
Surveillance, RNK, protection de l’écosystème, insecticide biologique, Côte d’Ivoire, Environmental Studies, onchocercose, vecteur, milieu aquatique, larve, insecticide chimique, NAT011000, méthode de lutte, parasite
Abstract

Since vector control began in 1975, waves of Simulium sirbanum and S. damnosum s.str., the principal vectors of severe blinding onchocerciasis in the West African savannas, have reinvaded treated rivers inside the original boundaries of the Onchocerciasis Control Programme in West Africa. Larviciding of potential source breeding sites has shown that these ‘savanna’ species are capable of travelling and carrying Onchocerca infection for at least 500 km northeastwards with the monsoon winds in the early rainy season. Vector control has, therefore, been extended progressively westwards. In 1984 the Programme embarked on a major western extension into Guinea, Sierra Leone, western Mali, Senegal and Guinea-Bissau. The transmission resulting from the reinvasion of northern Côte d’Ivoire and Burkina Faso has been reduced by over 95%, but eastern Mali has proved more difficult to protect because of sources in both Guinea and Sierra Leone. Rivers in Sierra Leone were treated for the first time in 1989 and biting and transmission rates in Sierra Leone and Guinea fell by over 90%. Because of treatment problems in some complex rapids and mountainous areas, flies still reinvaded Mali, though biting rates were approximately 70% lower than those recorded before anti-reinvasion treatments started. It was concluded that transmission in eastern Mali has now been reduced to the levels required to control onchocerciasis.

Published
2019

26. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study

Author

Elizabeth, A., primary, Jansen, L., additional, Hendrik, B., additional, Kloor, M., additional, Tagscherer, K., additional, Roth, W., additional, Boakye, D., additional, Herpel, E., additional, Grüllich, C., additional, Chang-Claude, J., additional, Brenner, H., additional, and Hoffmeister, M., additional

Published
2019
Full Text
View/download PDF

27. How can onchocerciasis elimination in Africa be accelerated? Modelling the impact of increased ivermectin treatment frequency and complementary vector control

Author

Verver, S, Walker, M, Kim, Y E, Fobi, G, Tekle, A H, Zouré, H G M, Wanji, S, Boakye, D A, Kuesel, A C, De Vlas, S J, Boussinesq, M, Basáñez, M-G, Stolk, W A, The Task Force for Global Health, Public Health, APH - Methodology, and APH - Global Health

Subjects
mass drug administration, Science & Technology, TRANSMISSION, Immunology, onchocerciasis, modeling, RIVER-BLINDNESS, 11 Medical And Health Sciences, 06 Biological Sciences, ECONOMIC-EVALUATION, EFFICACY, Microbiology, ivermectin, Infectious Diseases, elimination, VOLVULUS, CONTROL PROGRAM, Life Sciences & Biomedicine, WEST-AFRICA
Abstract

Background. Great strides have been made toward onchocerciasis elimination by mass drug administration (MDA) of ivermectin. Focusing on MDA-eligible areas, we investigated where the elimination goal can be achieved by 2025 by continuation of current practice (annual MDA with ivermectin) and where intensification or additional vector control is required. We did not consider areas hypoendemic for onchocerciasis with loiasis coendemicity where MDA is contraindicated. Methods. We used 2 previously published mathematical models, ONCHOSIM and EPIONCHO, to simulate future trends in microfilarial prevalence for 80 different settings (defined by precontrol endemicity and past MDA frequency and coverage) under different future treatment scenarios (annual, biannual, or quarterly MDA with different treatment coverage through 2025, with or without vector control strategies), assessing for each strategy whether it eventually leads to elimination. Results. Areas with 40%-50% precontrol microfilarial prevalence and >= 10 years of annual MDA may achieve elimination with a further 7 years of annual MDA, if not achieved already, according to both models. For most areas with 70%-80% precontrol prevalence, ONCHOSIM predicts that either annual or biannual MDA is sufficient to achieve elimination by 2025, whereas EPIONCHO predicts that elimination will not be achieved even with complementary vector control. Conclusions. Whether elimination will be reached by 2025 depends on precontrol endemicity, control history, and strategies chosen from now until 2025. Biannual or quarterly MDA will accelerate progress toward elimination but cannot guarantee it by 2025 in high-endemicity areas. Long-term concomitant MDA and vector control for high-endemicity areas might be useful.

Published
2017

34. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Author

Bousquet, Jean, Schunemann, H. J., Samolinski, B., Demoly, Pascal, Baena-Cagnani, C. E., Bachert, C., Bonini, S., Boulet, L. P., Brozek, J. L., Canonica, G. W., Casale, T. B., Cruz, A. A., Fokkens, W. J., Fonseca, J. A., Wick, R. G. van, Grouse, L., Haahtela, T., Khaltaev, N., Kuna, P., Lockey, R. F., Carlsen, K. C. Lodrup, Mullol, J., Naclerio, R. N., O'Hehir, R. E., Ohta, K., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pawankar, R., Price, D., Ryan, D., Simons, F. E. R., Togias, A., Williams, D. M., Yorgancioglu, A., Yusuf, O. M., Aberer, W., Adachi, M., Agache, I., Aït-Khaled, N., Akdis, C. A., Andrianarisoa, A., Annesi-Maesano, I., Ansotegui, I. J., Baiardini, I., Bateman, E. D., Bedbrook, Anna, Beghé, B., Beji, M., Bel, E. H., Kheder, A. Ben, Bennoor, K. S., Bergmann, K. C., Berrissoul, F., Bieber, T., Bindslev-Jensen, C., Blaiss, M. S., Boner, A. L., Bouchard, J., Braido, F., Brightling, C. E., Bush, A., Caballero-Fonseca, F., Calderon, M. A., Calvo, M. A., Camargos, P. A. M., Caraballo, L. R., Carlsen, K. H., Carr, W., A.M, Cepeda Sarabia, Cesario, A., Chavannes, Niels H., Chen, Y. Z., Chiriac, A. M., Pérez, T. Chivato, Chkhartishvili, E., Ciprandi, G., Costa, David J., Cox, L., Custovic, Adnan, Dahl, R., Darsow, U., Blay, F. De, Deleanu, D., Denburg, J. A., Devillier, P., Didi, T., Dokic, D., Dolen, W. K., Douagui, H. B., Dubakiene, R., Durham, S. R., Dykewicz, M. S., El-Gamal, Y., El-Meziane, A., Emuzyte, R., Fiocchi, A., Fletcher, M., Fukuda, T., Gamkrelidze, A., Gereda, J. E., Diaz, S. González, Gotua, M., Guzmán, M. A., Hellings, P. W., Hellquist-Dahl, B., Horak, F., Hourihane, J. O. B., Howarth, P. H., Humbert, M., Ivancevich, J. C., Jackson, Rod T., Just, J., Kalayci, O., Kaliner, M. A., Kalyoncu, A. F., Keil, T., Keith, P. K., Khayat, G., Kim, Y. Y., N'Goran, B. Koffi, Koppelman, G. H., Kowalski, M. L., Kull, I., Kvedariene, V., Larenas-Linnemann, D., Le, Tuyen D., Lemière, C., Li, J., Lieberman, P., Lipworth, B. J., Mahboub, B., Makela, M. J., Martin, F., Marshall, G. D., Martinez, F. D., Masjedi, M. R., Maurer, M., Mavale-Manuel, S., Mazon, A., Melén, E., Meltzer, E. O., Mendez, N. H., Merk, H., Mihaltan, F., Mohammad, Y., Almeida, M. Morais, Muraro, A., Nafti, S., Namazova-Baranova, L., Nekam, K., Neou, A., Niggemann, B., Nizankowska-Mogilnicka, E., Nyembue, T. D., Okamoto, Y., Okubo, K., Orru, M. P., Ouedraogo, S., Ozdemir, C., Panzner, P., Pali-Schöll, I., Park, H. S., Pigearias, B., Pohl, W., Popov, T. A., Postma, D. S., Potter, P., Rabe, K. F., Ratomaharo, J., Reitamo, S., Ring, J., Roberts, R., Rogala, B., Romano, A., Rodriguez, M. Roman, Rosado-Pinto, J., Rosenwasser, L., Rottem, M., Sanchez-Borges, M., Scadding, G. K., Schmid-Grendelmeier, P., Sheikh, A., Sisul, J. C., Sole, D., Sooronbaev, T., Spicak, V., Spranger, O., Stein, R. T., Stoloff, S. W., Sunyer, Jordi, Szczeklik, A., Todo-Bom, A., Toskala, E., Tremblay, Y., Valenta, R., Valero, A. L., Valeyre, D., Valiulis, A., Valovirta, E., Cauwenberge, P. Van, Vandenplas, O., Weel, C. Van, Vichyanond, P., Viegi, Giovanni, Wang, D. Y., Wickman, M., Wöhrl, S., Wright, J., Yawn, B. P., Yiallouros, Panayiotis K., Zar, H. J., Zernotti, M. E., Zhong, N., Zidarn, M., Zuberbier, T., Ang, C. S., Baigenzhin, A. K., Boakye, D. A., Briggs, A. H., Burney, P. G., Busse, W. W., Chuchalin, Alexander G., Haddad, H., Johnston, S. L., Kogevinas, M., Levy, L. M., Mohammadi, A., Oddie, S., Rezagui, D., Terreehorst, I., Warner, J. O., Bousquet, J, Schünemann, Hj, Samolinski, B, Demoly, P, Baena Cagnani, Ce, Bachert, C, Bonini, Sergio, AII - Amsterdam institute for Infection and Immunity, Ear, Nose and Throat, Pulmonology, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Custovic, Adnan [0000-0001-5218-7071], Hop Arnaud Villeneuve, INSERM, McMaster Univ, Med Univ Warsaw, Univ Hosp Montpellier, Catholic Univ, Univ Genoa, Univ Ghent, CNR, Univ Naples 2, Univ Laval, Creighton Univ, Universidade Federal da Bahia (UFBA), CNPq, Univ Amsterdam, Univ Porto, Hosp S Joao & Inst, Hosp CUF Porto, Erasmus MC, Univ Washington, Helsinki Univ Hosp, GARD ARIA Coordinator, Med Univ Lodz, Univ S Florida, James A Haley Vet Hosp, Univ Oslo, CIBERES, Univ Chicago, Alfred Hosp, Monash Univ, Teikyo Univ, EFA European Federat Allergy & Airways Dis Patien, Univ Athens, Nippon Med Sch, Univ Aberdeen, Woodbrook Med Ctr, Univ Edinburgh, Univ Manitoba, NIAID, Univ N Carolina, Celal Bayar Univ, Allergy & Asthma Inst, Med Univ Graz, Showa Univ, Transylvania Univ, Int Union TB & Lung Dis Union, Univ Zurich, Minist Hlth, Univ Paris 06, Hosp Quiron Bizkaia, Univ Cape Town, WHO, Univ Modena & Reggio Emilia, Ctr Hosp Univ Rabta, Hop Mami, Bangladesh Lung Fdn, Natl Inst Dis Chest & Hosp, Charite, Univ Med Ctr, Odense Univ Hosp, Univ Tennessee, Univ Verona, Hop Malbaie, Univ Leicester, Royal Brompton Hosp, Univ London Imperial Coll Sci Technol & Med, Ctr Med Docente La Trinidad Caracas, Univ Austral Chile, Univ Fed Sao Joao del Rei, Univ Cartagena, So Calif Res, Metropolitan Univ Barranquilla, IRCCS San Raffaele Pisana, Univ Cattolica Sacro Cuore, Leiden Univ, Capital Inst Pediat, Ctr Asthma Res & Educ, Univ Hosp, Georgian Natl Univ, Univ Montpellier I, Nova SE Univ, Univ Manchester, Aarhus Univ Hosp, Tech Univ Munich, TUM, Univ Hosp Strasbourg, Univ Med & Pharm Iuliu Hatieganu, Univ Versailles St Quentin, Ctr Hosp Reg Annecy, Univ Ss Cyril & Methodius, Georgia Hlth Sci Univ, Ctr Hosp Univ Beni Messous, Vilnius Univ, Wake Forest Univ, Ain Shams Univ, Egyptian Soc Pediat Allergy & Immunol, Soc Marocaine Malad Resp, Ctr Resp Dis & Allergy, Univ Milan, Educ Hlth, Dokkyo Med Univ, Clin Ricardo Palma, Univ Nuevo Leon UANL, Ctr Allergy & Immunol, Clin Hosp Univ Chile, Univ Hosp Leuven, Cent Reg Denmark, Allergy Ctr Vienna W, Natl Univ Ireland Univ Coll Cork, Univ Southampton, Univ Paris 11, Salvador Univ, Univ St Andrews, Univ Paris, Hacettepe Univ, George Washington Univ, Inst Asthma & Allergy, Hacettepe Univ Hosp, Hotel Dieu France, Univ St Joseph, Natl Med Ctr, Seoul Natl Univ, Korea Asthma Allergy Fdn, Ctr Hosp Univ, Univ Groningen, Karolinska Inst, Vilnius Univ Hosp Santariskiu Klinikos, Hosp Med Sur, Univ Med & Pharm, Hop Sacre Coeur Montreal, Univ Montreal, Guangzhou Med Univ, Univ Dundee, Dubai Hlth Author, Univ Sharjah, Univ Mississippi, Univ Arizona, Shahid Beheshti Univ Med Sci, Universidade Estadual de Maringá (UEM), Eduardo Mondlane Univ, Childrens Hosp La Fe, Karolinska Univ Hosp, Univ Calif San Diego, IMSS, Univ Aachen, Inst Pneumol Marius Nasta, Tishreen Univ, CUF Descobertas Hosp, Univ Padua, Mustapha Hosp, Sci Ctr Childrens Hlth RAMS, Hosp Hospitaller Bros Buda, German Red Cross Hosp Westend, Jagiellonian Univ, Kinshasa Univ, Chiba Univ Hosp, Ctr Hosp Univ Pediat Charles de Gaulle, Marmara Univ, Mem Hlth Grp, Charles Univ Prague, MESSERLI Res Inst, Med Univ Vienna, Univ Vienna, Ajou Univ, NICE, Soc Pneumol Langue Francaise, Krankenhaus Hietzing, Alexanders Univ Hosp, Groote Schuur Hosp, Grosshansdorf Clin, Hop Prive Athis Mons, Univ Wisconsin, Med Univ Silesia, Complesso Integrato Columbus, IRCCS Oasi Maria SS, Son Pisa Primary Care Ctr, Hosp Luz, Univ Missouri, Childrens Mercy Hosp, Emek Med Ctr, Technion Israel Inst Technol, Ctr Med Docente La Trinidad, UCL, Univ Zurich Hosp, Universidade Federal de São Paulo (UNIFESP), Natl Ctr Cardiol & Internal Med, Ctr ACI Immunoflow, GAAPP, Ctr Res Environm Epidemiol CREAL, Pontificia Univ Catolica RGS, Univ Nevada, Hosp Mar, CIBER Epidemiol & Salud Publ CIBERESP, Univ Pompeu Fabra UPF, Coimbra Univ Hosp, Childrens Hosp Philadelphia, Finnish Inst Occupat Hlth, Hosp Clin Barcelona, IDIBAPS, Univ Paris 13, Avicenne Hosp, Lithuanian Natl Council Childs Hlth, Terveystalo Turku, Univ Turku, Catholic Univ Louvain, Radboud Univ Nijmegen, Siriraj Hosp, Clin Physiol IFC, Natl Univ Singapore, Floridsdorf Allergy Ctr FAZ, Bradford Teaching Hosp Fdn Trust, Olmsted Med Ctr, Univ Minnesota, Harvard Univ, Cyprus Univ Technol, Catholic Univ Cordoba, Univ Clin Resp & Allerg Dis, Faculteit Medische Wetenschappen/UMCG, Groningen Research Institute of Pharmacy, Groningen Research Institute for Asthma and COPD (GRIAC), Dermatology, Internal Medicine, Erasmus MC other, Göğüs Hastalıkları, UCL - (MGD) Service de pneumologie, and UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie

Subjects
Allergy, WORLD-HEALTH-ORGANIZATION, GUIDELINES, Medical and Health Sciences, Primary-care, 0302 clinical medicine, QUALITY-OF-LIFE, Health care, Global health, Medicine, Immunology and Allergy, 030223 otorhinolaryngology, Child, Animals, Asthma, Clinical Trials as Topic, Europe, Humans, Practice Guidelines as Topic, Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal, World Health Organization, Persistent types, media_common, Rhinitis, PERSISTENT TYPES, PRIMARY-CARE, Effective primary care and public health [NCEBP 7], 3. Good health, GRADE, medicine.medical_specialty, Immunology, MEDLINE, World-health-organization, CONTROLLED-TRIAL, CLASSIFICATION, 03 medical and health sciences, Quality of life (healthcare), Allergic, EUROPEAN-UNION, rhinitis, Rhinitis, asthma, Allergic Rhinitis and its Impact on Asthma, allergy, GRADE, MANAGEMENT, media_common.cataloged_instance, Controlled-trial, Allergic Rhinitis and its Impact on Asthma, allergy, asthma, European union, Seasonal, business.industry, Guideline, medicine.disease, Perennial, 2008 UPDATE, Family medicine, Quality-of-life, Clinical Medicine, business, 030215 immunology
Abstract

Stallergenes ALK-Abello European Academy of Allergy and Clinical Immunology (EAACI) MSD Novartis Nycomed/Takeda PHADIA/Thermo Fischer 3M AstraZeneca GlaxoSmithKline Merck Frosst Altair Amgen Asmacure Boehringer-Ingelheim Genentech Pharmaxis Schering Wyeth Ache Brazilian Research Council Fundacao de Amparo a Pesquisa da Bahia Fundacao Ciencia e Tecnologia Sociedade Portuguesa de Alergologia e Immunologia Clinica Abdi Ibrahim OrionPharma Nasonebs Merck McNeal Chiesi Nycomed Air Liquid Healthcare Mundipharma Almirall Kyorin Teva UK National Health Service Aerocrine AKL Ltd PREDICTA Swiss National Science Foundation MeDALL Global Allergy and Asthma European Network (GA 2LEN) Christine Kuthe Center for Allergy Research and Education Faes Farma Bial Johnson Johnson Sanofi HAD treasurer Innovative Medicine Initiative (EU) Helse Sor-Ost RHF (Southern and Eastern Norway Regional Health Authority) MEDA Alcon ISTA Thermo-Fisher Airsonett Medical Research Council Moulton Charitable Trust AB Science Canadian Institutes for Health Research AllerGen NCE Merck/Schering-Plough Circassia University Hospital Medical School of Universidad Autonoma de Nuevo Leon, Mexico Children's Research Foundation (Ireland) Danone Food Standards Agency (United Kingdom) European Union (EU) DTG Netherlands Asthma Foundation Merck-Sharp-Dohme, Mexico Allerquim Mexico Abbott Apotex HRA MedImmune Schering-Plough Proctor Gamble Sunovion (Sepracor) Phadia Servier CSC JohnsonJohnson Oxygen Plus New Medics European Respiratory Society Societe de Pneumologie de Langue Francaise Asthma Ministry of Health, Welfare, and Labor Altana Takeda UCB Uriach advisory board NAPP Royal College of GPs Clinical Champion in Allergy Agency for Healthcare Research and Quality (AHRQ) AnseII Bayer Schering OST Fujisawa IHAL Henkel Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. in its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.) Kryolan Leti MSO Procter and Gamble Sanofi-Aventis Scientific Advisory Board for the German Society for Allergy and Clinical Immunology German Federal Ministry of Consumer Protection European Centre for Allergy Research Foundation (ECARF) Hop Arnaud Villeneuve, Dept Resp Dis, Univ Hosp, Montpellier, France INSERM, U1018, CESP Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, Villejuif, France McMaster Univ, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U657, Montpellier, France Catholic Univ, Fac Med, Res Ctr Resp Med CIMER, Cordoba, Argentina Univ Genoa, Sch Specializat, Genoa, Italy Univ Ghent, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium CNR, Inst Translat Pharmacol, Rome, Italy Univ Naples 2, Naples, Italy Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada Univ Genoa, Dept Internal Med, DIMI, I-16126 Genoa, Italy Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68178 USA Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil CNPq, Salvador, BA, Brazil Univ Amsterdam, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands Univ Porto, Sch Med, Dept Hlth Informat & Decis Sci, P-4100 Oporto, Portugal Univ Porto, Sch Med, CINTESIS, P-4100 Oporto, Portugal Hosp S Joao & Inst, Dept Allergy, Oporto, Portugal Hosp CUF Porto, Oporto, Portugal Erasmus MC, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands Univ Washington, Sch Med, Seattle, WA USA Helsinki Univ Hosp, Dept Allergy, Skin & Allergy Hosp, Helsinki, Finland GARD ARIA Coordinator, Geneva, Switzerland Med Univ Lodz, Dept Internal Med Asthma & Allergy, Barlicki Univ Hosp, Lodz, Poland Univ S Florida, Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33612 USA James A Haley Vet Hosp, Tampa, FL USA Univ Oslo, Oslo Univ Hosp, Dept Paediat, Oslo, Norway CIBERES, IDIBAPS, Hosp Clin, Rhinol Unit,ENT Dept, Barcelona, Spain CIBERES, IDIBAPS, Hosp Clin, Smell Clin,ENT Dept, Barcelona, Spain Univ Chicago, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia Monash Univ, Melbourne, Vic 3004, Australia Teikyo Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo 173, Japan EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece Nippon Med Sch, Bunkyo Ku, Tokyo 113, Japan Univ Aberdeen, Dept Primary Care Resp Med, Aberdeen, Scotland Woodbrook Med Ctr, Loughborough, Leics, England Univ Edinburgh, Edinburgh, Midlothian, Scotland Univ Manitoba, Fac Med, Winnipeg, MB, Canada NIAID, Bethesda, MD 20892 USA Univ N Carolina, Sch Pharm, Chapel Hill, NC USA Celal Bayar Univ, Sch Med, Dept Pulmonol, Manisa, Turkey Allergy & Asthma Inst, Islamabad, Pakistan Med Univ Graz, Dept Dermatol, Graz, Austria Showa Univ, Sch Med, Div Allergol & Resp Med, Tokyo 142, Japan Transylvania Univ, Fac Med, Brasov, Romania Int Union TB & Lung Dis Union, Paris, France Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland Minist Hlth, Publ Hosp Med Serv, Antananarivo, Madagascar INSERM, EPAR U707, Paris, France Univ Paris 06, EPAR, UMR S, Paris, France Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio Bilbao, Spain Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa WHO, Collaborating Ctr Asthma & Rhinitis, Montpellier, France Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Modena, Italy Ctr Hosp Univ Rabta, Serv Pneumol Allergol, Tunis, Tunisia Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands Hop Mami, Ariana, Tunisia Bangladesh Lung Fdn, Dhaka, Bangladesh Natl Inst Dis Chest & Hosp, Dhaka, Bangladesh Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany Univ Med Ctr, Dept Dermatol & Allergy, Bonn, Germany Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA Univ Verona, Dept Paediat, I-37100 Verona, Italy Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada Hop Malbaie, La Malbaie, PQ, Canada Univ Leicester, Inst Lung Hlth, Leicester LE1 7RH, Leics, England Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England Ctr Med Docente La Trinidad Caracas, Dept Immunol, Caracas, Venezuela Univ Austral Chile, Fac Med, Dept Pediat, Valdivia, Chile Univ Fed Sao Joao del Rei, Hlth Sci Ctr, Hlth Sci Postgrad Program, Divinopolis, Brazil Univ Cartagena, Immunol Res Inst, Cartagena de Indias, Colombia So Calif Res, Mission Viejo, CA USA Metropolitan Univ Barranquilla, Allergy & Immunol Lab, Barranquilla, Colombia IRCCS San Raffaele Pisana, Rome, Italy Univ Cattolica Sacro Cuore, Dept Thorac Surg, Rome, Italy Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands Capital Inst Pediat, Asthma Clin, Natl Cooperat Grp Pediat Res Asthma, Beijing, Peoples R China Capital Inst Pediat, Educ Ctr, Beijing, Peoples R China Ctr Asthma Res & Educ, Beijing, Peoples R China Hop Arnaud Villeneuve, Univ Hosp, Allergy Unit, Montpellier, France Univ Hosp, Dept Allergol, Sch Med CEU San Pablo Madrid, Madrid, Spain Georgian Natl Univ, AIETI Med Sch, SEU Clin, Med Ctr, Tbilisi, Rep of Georgia Univ Genoa, Dept Internal Med, IRCCS Azienda Osped Univ San Martino, I-16126 Genoa, Italy Univ Montpellier I, Primary Care Dept, Montpellier, France Nova SE Univ, Coll Osteopath Med, Davie, FL USA Univ Manchester, Manchester, Lancs, England Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany TUM, Div Environm Dermatol, Munich, Germany TUM, Allergy Helmholtz Ctr, Munich, Germany Univ Hosp Strasbourg, Chest Dis Dept, Div Pulmonol Asthma & Allergol, Strasbourg, France Univ Med & Pharm Iuliu Hatieganu, Dept Allergy, Med Clin 3, Romanian Soc Allergy & Clin Immunol, Cluj Napoca, Romania McMaster Univ, AllerGen NCE, Dept Med, Hamilton, ON, Canada McMaster Univ, AllerGen NCE, Michael G DeGroote Sch Med, Div Clin Immunol & Allergy,Fac Hlth Sci, Hamilton, ON, Canada Univ Versailles St Quentin, Hop Foch, UPRES EA 220, Suresnes, France Ctr Hosp Reg Annecy, Serv Pneumol, Annecy, France Univ Ss Cyril & Methodius, Univ Clin Pulmonol & Allergy, Skopje, Macedonia Georgia Hlth Sci Univ, Augusta, GA USA Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria Vilnius Univ, Fac Med, Collaborating Ctr GA2LEN, Vilnius, Lithuania Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt Egyptian Soc Pediat Allergy & Immunol, Cairo, Egypt Soc Marocaine Malad Resp, Casablanca, Morocco Ctr Resp Dis & Allergy, Casablanca, Morocco Vilnius Univ, Fac Med, Vilnius, Lithuania Univ Milan, Sch Med, Melloni Hosp, Milan, Italy Educ Hlth, Warwick, England Dokkyo Med Univ, Mibu, Tochigi, Japan WHO, Country Off Georgia, Tbilisi, Rep of Georgia Clin Ricardo Palma, Lima, Peru Univ Nuevo Leon UANL, Hosp Univ, Fac Med, Monterrey, Mexico Ctr Allergy & Immunol, Tbilisi, Rep of Georgia Clin Hosp Univ Chile, Dept Med, Immunol & Allergol Div, Santiago, Chile Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium Cent Reg Denmark, Ctr Publ Hlth & Qual Improvement, Aarhus, Denmark Allergy Ctr Vienna W, Vienna, Austria Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England Univ Paris 11, Serv Pneumol, Hop Antoine Beclere, AP HP,INSERM,U999, Clamart, France Salvador Univ, Sch Med, Dept Immunol, Buenos Aires, DF, Argentina Univ St Andrews, St Andrews, Fife, Scotland Univ Paris, APHP, Ctr Asthme & Allergies, Grp Hosp Trousseau La Roche Guyon, F-75252 Paris, France Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, Ankara, Turkey George Washington Univ, Sch Med, Washington, DC USA Inst Asthma & Allergy, Chevy Chase, MD USA Hacettepe Univ Hosp, Dept Chest Dis, Adult Allergy Unit, Ankara, Turkey Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany McMaster Univ, Hamilton, ON, Canada Hotel Dieu France, Serv Pneumol & Reanimat Med, Beirut, Lebanon Univ St Joseph, Fac Med, Beirut, Lebanon Natl Med Ctr, Seoul, South Korea Seoul Natl Univ, Seoul, South Korea Korea Asthma Allergy Fdn, Seoul, South Korea Ctr Hosp Univ, Serv Malad Resp, Abidjan, Cote Ivoire Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Beatrix Childrens Hosp,Dept Pediat Pulmonol & Ped, Groningen, Netherlands Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland Karolinska Inst, Dept Clin Sci & Educ, Stockholm, Sweden Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden Vilnius Univ, Ctr Pulmonol & Allergol, Vilnius, Lithuania Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico Univ Med & Pharm, Thanh Pho Ho Chi Minh, Vietnam Hop Sacre Coeur Montreal, Montreal, PQ, Canada Univ Montreal, Montreal, PQ, Canada Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China Univ Tennessee, Coll Med, Memphis, TN USA Univ Dundee, Ninewells Hosp, Asthma & Allergy Res Grp, Dundee, Scotland Dubai Hlth Author, Sharjah, U Arab Emirates Univ Sharjah, Sharjah, U Arab Emirates Univ Mississippi, Med Ctr, Div Clin Immunol & Allergy, Jackson, MS 39216 USA Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA Univ Arizona, Inst BIO5, Tucson, AZ USA Shahid Beheshti Univ Med Sci, NRITLD, Tehran, Iran Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Tehran, Iran Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany Maputo Cent Hosp, Dept Peadiat, Maputo, Mozambique Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique Childrens Hosp La Fe, Unit Pediat Allergy & Pneumol, Valencia, Spain Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden Univ Calif San Diego, Allergy & Asthma Med Grp, San Diego, CA 92103 USA Univ Calif San Diego, Res Ctr, San Diego, CA 92103 USA IMSS, Dept Allergy & Clin Immunol, Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico Univ Aachen, Dept Dermatol, Aachen, Germany Inst Pneumol Marius Nasta, Bucharest, Romania Tishreen Univ, Sch Med, Dept Internal Med, WHO EMRO Collaborating Ctr Training & Res Chron R, Latakia, Syria CUF Descobertas Hosp, Immunoallergy Dept, Lisbon, Portugal Univ Padua, Dept Pediat, Food Allergy Referral Ctr Veneto Reg, Padua, Italy Mustapha Hosp, Algiers, Algeria Sci Ctr Childrens Hlth RAMS, Moscow, Russia Hosp Hospitaller Bros Buda, Budapest, Hungary Charite, Allergie Ctr Charite ECARF, Dept Dermatol Venerol & Allergy, D-13353 Berlin, Germany German Red Cross Hosp Westend, Berlin, Germany Jagiellonian Univ, Sch Med, Dept Pulmonol, Krakow, Poland Kinshasa Univ, ENT Dept, Kinshasa, Zaire Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan Nippon Med Sch, Dept Otolaryngol, Bunkyo Ku, Tokyo 113, Japan Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey Mem Hlth Grp, Istanbul, Turkey Charles Univ Prague, Fac Med Plzen, Dept Immunol & Allergol, Prague, Czech Republic MESSERLI Res Inst, Vienna, Austria Med Univ Vienna, Univ Vet Med Vienna, Vienna, Austria Univ Vienna, Vienna, Austria Ajou Univ, Sch Med, Suwon 441749, South Korea NICE, Paris, France Soc Pneumol Langue Francaise, Paris, France Krankenhaus Hietzing, Karl Landsteiner Inst Expt & Clin Pneumol, Dept Pulm Med, Vienna, Austria Alexanders Univ Hosp, Clin Allergy & Asthma, Sofia, Bulgaria Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulmonol, Groningen, Netherlands Univ Cape Town, Lung Inst, ZA-7925 Cape Town, South Africa Groote Schuur Hosp, ZA-7925 Cape Town, South Africa Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands Grosshansdorf Clin, Grosshansdorf, Germany Hop Prive Athis Mons, Serv Pneumol, Athis Mons, France Helsinki Univ Hosp, Dept Dermatol, Skin & Allergy Hosp, Helsinki, Finland Tech Univ Munich, CKCARE, Dept Dermatol Allergy Biederstein, Munich, Germany Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA Med Univ Silesia, Dept & Clin Internal Dis Allergol & Clin Immunol, Katowice, Poland Complesso Integrato Columbus, Allergy Unit, Rome, Italy IRCCS Oasi Maria SS, Troina, Italy Son Pisa Primary Care Ctr, IB Salut Balear Hlth Serv, Int Primary Care Resp Grp, Palma de Mallorca, Spain Hosp Luz, Immunoallergy Dept, Lisbon, Portugal Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA Childrens Mercy Hosp, Kansas City, MO USA Emek Med Ctr, Afula, Israel Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel Ctr Med Docente La Trinidad, Dept Allergy & Clin Immunol, Caracas, Venezuela UCL, Royal Natl TNE Hosp, London, England Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan Ctr ACI Immunoflow, Czech Initiat Asthma, Prague, Czech Republic GAAPP, Vienna, Austria Ctr Res Environm Epidemiol CREAL, Barcelona, Spain Pontificia Univ Catolica RGS, Sch Med, Porto Alegre, RS, Brazil Univ Nevada, Sch Med, Reno, NV 89557 USA Hosp Mar, Municipal Inst Med Res IMIM, Barcelona, Spain CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain Univ Pompeu Fabra UPF, Barcelona, Spain Jagiellonian Univ, Coll Med, Krakow, Poland Coimbra Univ Hosp, Immunoallergy Dept, Coimbra, Portugal Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA Finnish Inst Occupat Hlth, Helsinki, Finland Univ Laval, Fac Med, Dept Obstet & Gynecol, Laval, PQ, Canada Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria Hosp Clin Barcelona, Dept Pneumol, Allergy Unit, Immunoallergia Resp Clin, Barcelona, Spain IDIBAPS, Barcelona, Spain CIBERES, Barcelona, Spain Univ Paris 13, Bobigny, France Avicenne Hosp, AP HP, Bobigny, France Vilnius Univ, Fac Med, Dept Paediat, Vilnius, Lithuania Lithuanian Natl Council Childs Hlth, Vilnius, Lithuania Terveystalo Turku, Allergy Clin, Turku, Finland Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium Catholic Univ Louvain, Univ Hosp Mt Godinne, Yvoir, Belgium Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand CNR, IBIM, Palermo, Italy Clin Physiol IFC, Pisa, Italy Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore Floridsdorf Allergy Ctr FAZ, Vienna, Austria Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria Bradford Teaching Hosp Fdn Trust, Bradford Inst Hlth Res, Bradford, W Yorkshire, England Olmsted Med Ctr, Dept Res, Rochester, MN USA Univ Minnesota, Dept Family & Community Hlth, Rochester, MN USA Harvard Univ, Sch Publ Hlth, Cyprus Int Inst Environm & Publ Hlth Assoc, Limassol, Cyprus Cyprus Univ Technol, Limassol, Cyprus Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, ZA-7925 Cape Town, South Africa Catholic Univ Cordoba, Sch Med, Dept Otorhinolaryngol, Cordoba, Argentina Guangzhou Med Univ, Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China Univ Clin Resp & Allerg Dis, Golnik, Slovenia Charite, Network Excellence, Global Allergy & Asthma European Network GA2LEN, D-13353 Berlin, Germany Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil Web of Science

Published
2012

39. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana

Author

Awadzi, K., primary, Boakye, D. A., additional, Edwards, G., additional, Opoku, N. O., additional, Attah, S. K., additional, Osei-Atweneboana, M. Y., additional, Lazdins-Helds, J. K., additional, Ardrey, A. E., additional, Addy, E. T., additional, Quartey, B. T., additional, Ahmed, K., additional, Boatin, B. A., additional, and Soumbey-Alley, E. W., additional

Published
2004
Full Text
View/download PDF

40. Development and standardization of a rapid, PCR-based method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring the human prevalence of bancroftian filariasis

Author

Williams, S. A., primary, Laney, S. J., additional, Bierwert, L. A., additional, Saunders, L. J., additional, Boakye, D. A., additional, Fischer, P., additional, Goodman, D., additional, Helmy, H., additional, Hoti, S. L., additional, Vasuki, V., additional, Lammie, P. J., additional, Plichart, C., additional, Ramzy, R. M. R., additional, and Ottesen, E. A., additional

Published
2002
Full Text
View/download PDF

50. Field and laboratory studies on water conditions affecting the potency of VectoBac® ( Bacillus thuringiensis serotype H-14) against larvae of the blackfly, Simulium damnosum.

Author

Wilson, M. D., Akpabey, F. J., Osei-Atweneboana, M. Y., Boakye, D. A., Ocran, M., Kurtak, D. C., Cheke, R. A., Mensah, G. E., Birkhold, D., and Cibulsky, R.

Subjects
BACILLUS thuringiensis, SIMULIUM arcticum, MICROBIAL insecticides, RESEARCH, DEVELOPMENTAL biology
Abstract

River water conditions that might influence the efficacy of VectoBac®, a formulation of the microbial insecticide Bacillus thuringiensis H-14 Berliner against Simulium damnosum sensu lato Theobald (Diptera: Simuliidae) larvae were investigated. A standard formulation was assayed 130 times over 15 months using a mini-gutter system at a field station beside the River Pra in Ghana. The lethal concentration (LC) values, river temperature, conductivity, turbidity and pH were analysed using univariate and multivariate statistics to identify which of these parameters influenced its performance. River temperature, conductivity and turbidity (in that order) were identified as having direct effects on the potency of VectoBac®. Water temperature and conductivity were negatively correlated, whereas turbidity and pH were positively correlated with LC values. Analyses of river water samples revealed that despite observed differences in total solids, sodium and potassium cations and chloride concentrations, all the parameters measured did not differ significantly between wet and dry seasons. A simple method for rearing S. damnosum s.l. in the laboratory was then adopted to study the effect of conductivity on potency of VectoBac® under controlled conditions. Increasing the conductivity of the water medium up to 3000 µS enhanced potency by about 42%, whereas increasing that of the insecticide alone raised it by 37%. The results obtained suggest that for effective use of VectoBac® for blackfly control in West Africa, river temperature, conductivity and turbidity should be taken into consideration, perhaps by only selecting rivers with optimal conditions for treatment. The laboratory-based system developed for assaying the product overcomes the vagaries associated with field conditions and also the demand for huge logistic requirements of the mini-gutter system, which has to be sited near rivers. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results